euSEND

Neglected diseases, such as malaria, represent a major health, societal and economic burden on developing countries. Within its project portfolio, TI Pharma is seeking to develop solutions to these diseases, mobilizing public and private partners in multilateral consortia - bringing together a wide range of competences and resources.

As the first showcase of euSEND, three projects are being initiated with FIND (Foundation for Innovative New Diagnostics), a not-for-profit foundation focusing on improving the diagnosis of diseases in developing countries. The projects will focus on leishmaniasis, trachoma and tuberculosis. Other partners involved are Leiden University Medical Center and the Royal Tropical Institute (KIT).

Learn more about our projects on neglected diseases >> 

euSEND is a joint initiative of the Academic Medical Center of the University of Amsterdam (AMC), the Royal Tropical Institute (KIT), the Amsterdam Institute for Global Health and Development (AIGHD), Roland Berger Strategy Consultants and Top Institute Pharma.

To learn more about euSEND visit the euSEND website

if you are interested in learning more on these projects, please contact Jayasree Iyer at 071 332 2047 or e-mail jay.iyer@tipharma.com.